Analyst Warns of Revenue Uncertainty for Chinese Pharmaceutical Contractors Amid US Supply Chain Shifts
According to an analyst from Jefferies, Chinese contract drug manufacturers such as WuXi AppTec, WuXi Biologics, and WuXi XDC are experiencing reduced long-term revenue prospects due to US pharmaceutical firms moving production domestically and adjusting supply chains in response to escalating US-China tensions. While earnings for the near future remain stable, visibility beyond that period is limited, with strong revenue momentum expected only through 2026 and 2027.
Key facts
- Chinese contract drug makers face uncertain long-term revenue outlook
- US pharmaceutical companies are reshoring production and reconfiguring supply chains
- Near-term earnings are stable, but visibility beyond that is limited according to Jefferies analyst Cui Cui
Entities
Institutions
- WuXi AppTec
- WuXi Biologics
- WuXi XDC
- Jefferies
Locations
- China
- US